Ryan Burdick
Family · Fresno, CANPI 1881970572
Payments from drug & device makers
Across 79 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$296
- AstraZeneca$250
- Boehringer Ingelheim$173
- Bayer$98
- Novo Nordisk$69
- GSK$61
- plus $593 from 19 others
What the payments were for
- Food & beverage$1,52899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $296 |
| AstraZeneca | 11 | $250 |
| Boehringer Ingelheim | 9 | $173 |
| Bayer | 4 | $98 |
| Novo Nordisk | 4 | $69 |
| GSK | 4 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Dexcom, Inc. | 2 | $46 |
| Amgen | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Abbott | 2 | $41 |
| Johnson & Johnson | 2 | $41 |
| AbbVie | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Shield Therapeutics Inc | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Merck | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$1,540 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 124 | $178,696 |
| OzempicSemaglutide | 82 | $111,598 |
| RybelsusSemaglutide | 58 | $99,853 |
| EliquisApixaban | 45 | $49,817 |
| JanuviaSitagliptin Phosphate | 48 | $44,316 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $41,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $39,635 |
| XifaxanRifaximin | 12 | $27,788 |
| FarxigaDapagliflozin Propanediol | 19 | $26,285 |
| MounjaroTirzepatide | 22 | $21,999 |
| TradjentaLinagliptin | 18 | $21,648 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $20,485 |
| LinzessLinaclotide | 23 | $19,993 |
| XareltoRivaroxaban | 12 | $19,743 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $15,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $69 | $211,450140 claims |
| Boehringer IngelheimJardiance, Tradjenta | $173 | $200,344142 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $61 | $101,55687 claims |
| MerckJanuvia | $16 | $44,31648 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $57 | $27,78812 claims |
| Johnson & JohnsonXarelto, Invokana | $41 | $27,75723 claims |
| AstraZenecaFarxiga | $250 | $26,28519 claims |
| Lilly USA, LLCMounjaro | $296 | $21,99922 claims |
| AbbVieLinzess | $37 | $19,99323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $14,67416 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,459203 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.
Other family in Fresno
- Freddy EspinozaFresno$33K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.